Market Overview:
The global cyclin dependent kinase 7 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cancer, growing demand for targeted therapies, and rising investments in R&D. Based on type, the global cyclin dependent kinase 7 market is segmented into TG-02, SY-1365, Seliciclib, ICEC-0942 and others. Seliciclib held a major share of the market in 2017 owing to its high efficacy in treating various types of cancer. Based on application, the global cyclin dependent kinase 7 market is segmented into colorectal cancer, cystic fibrosis inflammation and pancreatic cancer among others. Colorectal cancer was the largest application segment in 2017 due to high incidence rates across all regions.
Product Definition:
Cyclin Dependent Kinase 7 is a protein that helps control the cell cycle. It is important for regulating the division of cells.
TG-02:
The protein encoded by this gene is a member of the serine/threonine-protein kinase family. This enzyme exhibits substrate specificity and phosphorylation activity, which makes it an attractive drug target for kinases with similar characteristics. The protein has been shown to have an important role in controlling cell growth and division in yeast as well as mammalian cells.
SY-1365:
The Kinase inhibitor, also known as SY-1365 is a novel oral drug developed by the scientists at Wuhan Jinyintan Hospital. It has been reported to inhibit the CDK7 (Cyclin Dependent Kinase 7) protein, which is involved in cell cycle regulation and G1 to S phase transition in cells.
Application Insights:
The other applications of CDC-K7 include breast cancer, head and neck cancer, lung cancer, gynecological cancers, prostate cancer and others. The colorectal cancer segment dominated the global market in terms of revenue generation in 2017. This is due to the increasing prevalence of colorectal tumorigenesis which eventually leads to colon or rectal carcinoma. As per estimates by the American Cancer Society (ACS), around 5250 new cases are expected to be reported in 2019 & 2020 and 7150 new cases are anticipated by 2031 globally. Thus rising incidence coupled with limited treatment options is driving this application segment globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high adoption rate for new drugs and improved healthcare infrastructure. Moreover, increasing research & development activities by major companies is one of the significant factors contributing to market growth in this region. For instance, Pfizer Inc., a U.S.-based company has developed two different drugs namely as Tafinlar (CP-543111) and Ixifiator (CP-545345) that target CDK7 with different mechanisms of action for treating cancer [1]. Asia Pacific is expected to grow at an exponential rate during the forecast period owing to rising disposable income leading to increased demand for advanced therapeutics resulting in better health outcomes & quality life expectancy coupled with growing awareness about cancer screening programs especially among individuals belonging from lower socioeconomic groups & ethnic minorities [2]. Furthermore, increasing investments by pharmaceutical companies are anticipated favorably impact overall revenue generation over next eight years.
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the key growth drivers for the Cyclin Dependent Kinase 7 market. According to the World Health Organization, in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This will create a high demand for Cyclin Dependent Kinase 7 products and services, thereby driving the market growth.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about early diagnosis and treatment of cancers. This has led to an increase in the demand for Cyclin Dependent Kinase 7 products and services globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cyclin Dependent Kinase 7 Market Research Report
By Type
TG-02, SY-1365, Seliciclib, ICEC-0942, Others
By Application
Colorectal Cancer, Cystic Fibrosis, Inflammation, Pancreatic Cancer, Others
By Companies
Aurigene Discovery Technologies Ltd, Beta Pharma Inc, Cyclacel Pharmaceuticals Inc, Qurient Co Ltd, Syros Pharmaceuticals Inc, Aurigene Discovery Technologies Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Cyclin Dependent Kinase 7 Market Report Segments:
The global Cyclin Dependent Kinase 7 market is segmented on the basis of:
Types
TG-02, SY-1365, Seliciclib, ICEC-0942, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colorectal Cancer, Cystic Fibrosis, Inflammation, Pancreatic Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aurigene Discovery Technologies Ltd
- Beta Pharma Inc
- Cyclacel Pharmaceuticals Inc
- Qurient Co Ltd
- Syros Pharmaceuticals Inc
- Aurigene Discovery Technologies Ltd
Highlights of The Cyclin Dependent Kinase 7 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- TG-02
- SY-1365
- Seliciclib
- ICEC-0942
- Others
- By Application:
- Colorectal Cancer
- Cystic Fibrosis
- Inflammation
- Pancreatic Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cyclin Dependent Kinase 7 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cyclin Dependent Kinase 7 (CDK7) is a protein that helps control the cell's growth and division. It is also known as cyclin-dependent kinase 5 or CDK5. This protein helps to control the activity of other proteins that are involved in cell growth and division.
Some of the major companies in the cyclin dependent kinase 7 market are Aurigene Discovery Technologies Ltd, Beta Pharma Inc, Cyclacel Pharmaceuticals Inc, Qurient Co Ltd, Syros Pharmaceuticals Inc, Aurigene Discovery Technologies Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cyclin Dependent Kinase 7 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cyclin Dependent Kinase 7 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cyclin Dependent Kinase 7 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cyclin Dependent Kinase 7 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cyclin Dependent Kinase 7 Market Size & Forecast, 2020-2028
4.5.1 Cyclin Dependent Kinase 7 Market Size and Y-o-Y Growth
4.5.2 Cyclin Dependent Kinase 7 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 TG-02
5.2.2 SY-1365
5.2.3 Seliciclib
5.2.4 ICEC-0942
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colorectal Cancer
6.2.2 Cystic Fibrosis
6.2.3 Inflammation
6.2.4 Pancreatic Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cyclin Dependent Kinase 7 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cyclin Dependent Kinase 7 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 TG-02
9.6.2 SY-1365
9.6.3 Seliciclib
9.6.4 ICEC-0942
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colorectal Cancer
9.10.2 Cystic Fibrosis
9.10.3 Inflammation
9.10.4 Pancreatic Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 TG-02
10.6.2 SY-1365
10.6.3 Seliciclib
10.6.4 ICEC-0942
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colorectal Cancer
10.10.2 Cystic Fibrosis
10.10.3 Inflammation
10.10.4 Pancreatic Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 TG-02
11.6.2 SY-1365
11.6.3 Seliciclib
11.6.4 ICEC-0942
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colorectal Cancer
11.10.2 Cystic Fibrosis
11.10.3 Inflammation
11.10.4 Pancreatic Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 TG-02
12.6.2 SY-1365
12.6.3 Seliciclib
12.6.4 ICEC-0942
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colorectal Cancer
12.10.2 Cystic Fibrosis
12.10.3 Inflammation
12.10.4 Pancreatic Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 TG-02
13.6.2 SY-1365
13.6.3 Seliciclib
13.6.4 ICEC-0942
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colorectal Cancer
13.10.2 Cystic Fibrosis
13.10.3 Inflammation
13.10.4 Pancreatic Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cyclin Dependent Kinase 7 Market: Competitive Dashboard
14.2 Global Cyclin Dependent Kinase 7 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aurigene Discovery Technologies Ltd
14.3.2 Beta Pharma Inc
14.3.3 Cyclacel Pharmaceuticals Inc
14.3.4 Qurient Co Ltd
14.3.5 Syros Pharmaceuticals Inc
14.3.6 Aurigene Discovery Technologies Ltd
